Henry Schein Expands Exclusive U.S. Distribution of Curodont
Key Points
- Henry Schein has expanded its exclusive U.S. distribution agreement with Swiss company vVARDIS for the drill-free cavity treatment product Curodont Repair Fluoride Plus.
- The expanded agreement, effective January 1, 2026, extends distribution from Dental Service Organizations to include general dentistry, orthodontics, and pediatric dentistry nationwide.
- Curodont is a proprietary, drill- and needle-free solution for treating early-stage cavities, addressing a significant unmet need in dental care.
- The expansion follows Henry Schein's strong third-quarter 2025 earnings and reflects the product's rapid adoption, having reached over 10% of U.S. dental offices and treated more than 500,000 patients.
Expansion of Exclusive Distribution Agreement
Henry Schein, Inc., a leading global provider of healthcare solutions to office-based dental and medical practitioners, announced on December 1, 2025, the expansion of its exclusive U.S. distribution agreement with vVARDIS, a Swiss healthcare company. This agreement grants Henry Schein exclusive rights to distribute Curodont Repair Fluoride Plus, a drill-free cavity treatment product, across all U.S. dental market segments starting January 1, 2026. Previously, the exclusivity was limited to Dental Service Organizations (DSOs) as established in a 2024 agreement. The expansion now includes general dentistry, orthodontics, and pediatric dentistry nationwide, significantly broadening the product's market reach. This strategic move aims to strengthen Henry Schein's position in the dental supplies market and enhance its portfolio of innovative dental care solutions.
About Curodont Repair Fluoride Plus and Its Market Impact
Curodont Repair Fluoride Plus is a proprietary biomimetic solution developed by vVARDIS that treats early-stage cavities without the need for drilling or needles. This non-invasive approach addresses a critical gap in dental care, as up to 80% of patients present with early-stage cavities that often go untreated, increasing the risk of more serious oral and systemic health issues. The product's application is simple and patient-friendly, enabling dental professionals to expand their treatment offerings and improve patient outcomes. Scientific studies, including those published in the International Journal of Epidemiology, have linked untreated cavities and poor oral health to higher all-cause and heart disease mortality, underscoring the importance of early intervention. Curodont's success is supported by over 25 years of research, more than 230 scientific publications, and clinical studies demonstrating a success rate above 90%.
Business and Strategic Significance for Henry Schein
The expanded distribution agreement with vVARDIS aligns with Henry Schein's mission to provide innovative healthcare solutions that improve operational success and clinical outcomes for dental practitioners. Stanley M. Bergman, Chairman and CEO of Henry Schein, emphasized that the expansion reflects a shared commitment to helping dental professionals operate more efficient practices while advancing oral and overall health in their communities. Henry Schein is currently the market leader in selling Curodont to general practitioners and DSOs in the United States and also holds exclusive distribution rights for the product in the United Kingdom, with non-exclusive rights in other regions. The company operates a centralized and automated distribution network with a broad product portfolio, supporting over one million customers globally. Henry Schein's sales reached $12.7 billion in 2024, with a compound annual growth rate of approximately 11.2% since going public in 1995.
vVARDIS’s Role and Growth with Henry Schein Partnership
vVARDIS, headquartered in Zug, Switzerland, is a high-growth healthcare company founded by Drs. Haley and Goly Abivardi, who are also the Co-CEOs. The company focuses on developing non-invasive dental solutions under the Curodont brand, aiming to improve oral health as a foundation for overall health. The decision to expand the partnership with Henry Schein was driven by the product's exceptional success in the U.S. market, where it has accessed over 10% of dental offices and treated more than 500,000 patients. The founders highlighted the foundation of trust, shared goals, and delivered growth as key reasons for choosing Henry Schein as the exclusive partner to make Curodont accessible to the entire U.S. dental community. This collaboration is expected to accelerate the adoption of innovative dental care solutions and improve patient access to effective, minimally invasive treatments.
Key Takeaways
- Henry Schein will exclusively distribute vVARDIS’s Curodont Repair Fluoride Plus across all U.S. dental segments starting in 2026, expanding beyond Dental Service Organizations.
- Curodont offers a drill- and needle-free treatment for early-stage cavities, addressing a large unmet need in dental care and potentially improving overall health outcomes.
- The expanded partnership reflects strong market adoption and aligns with Henry Schein’s strategy to provide innovative, efficient solutions to dental professionals.
References
- 1. https://finance.yahoo.com/news/henry-schein-expands-partnership-vvardis-213400510.html
- 2. https://www.stocktitan.net/news/HSIC/henry-schein-expands-partnership-with-v-tgammh7rbnhy.html
- 3. https://za.investing.com/news/company-news/henry-schein-expands-vvardis-distribution-deal-for-drillfree-cavity-treatment-93CH-4007572
- 4. https://in.investing.com/news/company-news/henry-schein-expands-vvardis-distribution-deal-for-drillfree-cavity-treatment-93CH-5132318
Get premium market insights delivered directly to your inbox.